Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT03203473 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Renal Cancer

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Toni Choueiri, MD

Collaborators

[object Object]